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Abstract 
Postulating that serotonin, secreted from smoking-activated platelets, could be involved in 
smoking-induced vascular modifications, we studied 115 men distributed in smokers (S), 
former smokers (FS) and never smokers (NS). The platelet serotonin content was similar in S 
and NS but lower in FS. This was unexpected because the monoamine oxidase (MAO) 
activity, which catabolizes serotonin, was inhibited during smoking. However, the amount of 
platelet MAO was higher in S and FS than in NS. The persistent elevated MAO amount in FS 
prompted us to study the methylation of its gene promoter in an additional series of patients: it 
was markedly lower for S and FS vs. NS due to cigarette smoke-induced increase of nucleic 
acid demethylase activity. This smoking-induced demethylation of the MAO gene promoter, 
resulting in high MAO amount persisting long after quitting smoking, has cardiovascular 
consequences and could impact fields such as behavior, mental health, and cancer. 
 
Key words: smoking, serotonin, monoamine oxidase, gene methylation 
 
 
 
 
 
 
 
 3
Serotonin (5-hydroxytryptamine, 5-HT) is a potent biogenic amine, first described as the 
vasoconstrictor compound contained in the serum and later identified as a neurotransmitter1. 
Once synthesized in the gastrointestinal tract, peripheral serotonin is actively incorporated by 
platelets which store the amine within their dense granules. As a result, serotonin is widely 
distributed in the body through the blood flow. Under normal physiological conditions, 
platelet granule-stored 5-HT can be either delivered into blood flow through the open 
canalicular system or exposed to the platelet mitochondrial monoamine oxidase (MAO). In 
the latter case, it is degraded into 5-hydroxyindole acetic acid (5-HIAA) which also passes 
through the open canalicular system towards blood. However, the platelet storage of serotonin 
occurs against such a high concentration gradient that it protects the organism from serotonin-
induced vascular tone abrupt modifications, maintains the serotonin plasma level in the low 
nM range and prevents the amine of being degraded.  
Degradation of serotonin mainly occurs through monoamine oxidases (MAOs). There are two 
MAO isoforms: MAO-A preferentially degrades endogenous bioamines such as serotonin and 
norepinephrine, and MAO-B preferentially degrades exogenous bioamines such as 
phenylethylamine and benzylamine2. These specificities are relative however. Human 
platelets and lymphocytes contain only the MAO-B isoform. Human MAOA and MAOB genes 
are both located on the short arm of the X chromosome (Xp.11.4-11.3). The two genes are 
arranged in a tail-to-tail orientation, and both span at least 60 kb, consist of 15 exons, and 
exhibit an identical exon-intron organization2. 
Serotonin has been proposed to be predictive of coronary artery diseases especially in young 
people3. In addition, inhibitors of 5-HT incorporation, the so-called specific serotonin 
reuptake inhibitors (SSRIs) used as major depression therapy4, reduce the cardiovascular 
complications of these patients by inhibiting platelet activation and aggregation5. We 
therefore decided to measure the platelet serotonin level and to study its catabolism in a series 
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of untreated men at low risk for cardiovascular disease. Unexpectedly, the greatest 
modifications in serotonin catabolism were found in former smokers (FS) rather than in 
current smokers (S) as compared to patients who had never smoked (NS). We found that 
smoking induced an epigenetic regulation of MAOB, i.e. a reduction of its gene promoter 
methylation, resulting in high MAO amounts which persist long after (over 10 years) quitting 
smoking.  
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RESULTS 
Characteristics of patients 
With the aim to study the impact of smoking on platelet activation, independently of other 
cardiovascular risk factors such as diabetes and hormonal factors, the men population was 
carefully selected as untreated and free of any major cardiovascular risk. The clinical profile 
of the studied population in relation with the smoking status is shown in Table 1 and 
Supplementary Table 1. The smoking group was typical6, i.e. with more femoral plaques 
and higher number of atherosclerotic sites. Smoking duration was higher in S than in FS 
group (P < 0.05) but lifelong cumulative consumption, as reflected by pack.years, was not 
different between the two groups. The number of patients having one or more plaque(s) at any 
site, and more specifically one or more femoral plaque(s) was significantly higher in the S 
group than in the FS and NS groups (P < 0.01). 
 
Platelet aggregation, platelet 5-HT and plasma 5-hydroxyindole acetic acid (5-HIAA) 
Because, so far, most studies dealing with smoking have compared S and NS, we initially 
considered only two groups, i.e. current smokers [S] and presently-non-smokers who had not 
smoked for at least one year on the day of blood sampling (including never smokers [NS] and 
former smokers [FS]). In response to 2 μg/ml collagen, platelet aggregation amplitude in 
whole blood was similar in the two groups (16 ± 5 vs. 16 ± 4 ohms), whereas the aggregation 
velocity (ohms.min-1) was significantly lower (P < 0.01) in smokers (7.9 ± 0.5) than in 
presently-non-smokers (10.3 ± 0.6). The platelet 5-HT content was almost identical in the two 
groups (S and NS + FS), as was plasma 5-HIAA, the main 5-HT catabolite (Fig. 1a,b).  
This surprising lack of differences between current smokers (S) and presently-non-smokers 
(NS + FS) prompted us to further analyze NS + FS in order to differentiate those who had 
never smoked (NS) from those who had smoked but had quitted one year ago or more, i.e. 
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former smokers (FS). The less rapid aggregation of smokers’ platelets was confirmed 
(velocity 7.9 ± 0.5 ohms.min-1 for S vs. 10 ± 0.6 and 11 ± 1 for FS and NS respectively, P < 
0.01), indicating that platelet aggregation velocity was back to normal after quitting smoking.  
The discrimination of FS in the non-smoking group allowed us to evidence that FS had a 
significantly reduced platelet amount of 5-HT as compared to NS and S (Fig. 1a). We thus 
hypothesized that 5-HT was released from the storage granules of FS platelets and, once 
released, was degraded into 5-HIAA. Indeed, the 5-HIAA amounts measured in FS plasmas 
were significantly higher than in NS and S (Fig. 1b). 
 
Platelet monoamine oxidase  
The fact that platelet 5-HT was more degraded into 5-HIAA suggested that the enzyme 
responsible for this degradation, MAO, was either more active or more abundant in FS. We 
thus measured both MAO activity and MAO amount in platelets, the most easily accessible 
source of MAO. As previously reported2,7,8, we confirmed that MAO-B (the only isoenzyme 
present in human platelets) activity was significantly weaker in current smokers than in 
presently-non-smokers (Fig. 1c). But when discriminating FS in the non smoking group, 
MAO-B activity was found at a similar level in S and NS, whereas it was significantly greater 
in FS (Fig. 1c). 
This high platelet MAO activity found in FS was explained by a higher MAO-B amount than 
in NS as assessed by both binding and western blot (Fig. 1d). Unexpectedly however, the 
platelet MAO amount was also high in S (Fig. 1d). This prompted us to calculate for each 
donor the enzyme catalytic activity, i.e. the ratio of MAO-B activity to its amount. This 
evidenced that the lowest mean MAO-B catalytic activity was that of S platelets where one 
enzyme molecule hydrolyzed 9,000 molecules of substrate per hour as compared to NS 
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(13,000) and FS (11,000). Platelet 5-HT and plasma 5-HIAA levels were highly correlated 
(P<0.001, not shown) with both platelet MAO activities and amounts.  
The present results reassert that MAO-B activity is inhibited by smoking and reveal for the 
first time that (i) platelet MAO-B amount increased during smoking and (ii) this increase 
lasted long after quitting smoking (13 yrs average in our group of FS). 
 
Methylation of the MAO gene promoter  
The platelet MAO-B amount remaining elevated several years after quitting smoking 
suggested a smoking-induced gene modification. A detailed analysis reported that the human 
MAOB core promoter contains 22 CpG sites that can be methylated, with methylation 
reducing the transcription of MAOB9. We therefore analyzed the methylation patterns of the 
MAOB core promoter in a new series (5 S, 4 FS, 4 NS) clinically identical to the initial cohort 
(Supplementary Table 2). As for the previous population, the MAO-B amount was the 
lowest in NS patients, whereas the MAO-B activity was higher in FS (Fig. 2 insert).  
DNA analysis was performed on peripheral blood mononuclear cells (PBMC) of S, FS and 
NS subjects, which exhibited similar MAO profiles as platelets (Supplementary Fig. 1). The 
methylation frequency was notably higher for NS, both at each of the 22 sites (Fig. 2a, left) or 
as the mean of the 22 sites (Fig. 2a, right). According to the repressing effect of DNA 
methylation upon general gene transcription10 and upon specific transcription of the human 
MAOB9, the individual methylation frequencies were negatively correlated with the platelet 
MAO-B amounts of the 13 studied patients (Fig. 2b). These findings bring an explanation for 
the high MAO-B amount long-lasting after quitting smoking.  
In addition, in order to verify that tobacco smoke is truly responsible for this methylation 
change, DNA methyltransferase and nucleic acid demethylase activities were measured in 
lung nuclear extracts of mice exposed to cigarette smoke. Interestingly, these mice exhibited 
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lung MAO profiles (MAO-B and MAO-A, Fig. 3a) comparable to those found in human S 
patient’s platelets, i.e. higher amounts and lower activity in Sm than in “non-smoking” mice 
(NSm). Noteworthy, the MAO profile of mice platelets (MAO-B, Fig. 3 insert) was also 
comparable. The lung DNA methyltransferase activity appeared not significantly different 
(Fig. 3b), whereas the nucleic acid demethylase activity was significantly higher in 
“smoking” mice (Sm, Fig. 3c). Moreover, the in vitro nucleic acid demethylase activity of 
mouse lung nuclear extracts was increased by harman and norharman, two known inhibitors 
of MAO activities present in tobacco smoke11,12. This demethylase activity increase was of 
12.3 ± 0.4 and 9.6 ± 0.5 % for harman and norharman (100 nM), respectively (n = 3).  
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DISCUSSION 
The present report is one of the very few to differentiate former smokers (FS) from those who 
have never smoked in terms of platelet 5-HT catabolism. We showed that the 5-HT content 
was significantly reduced in platelets of FS who had quitted smoking for a mean of 13 years. 
This smoking-induced long-lasting effect was due to demethylation of the MAOB gene 
promoter which resulted in a persisting high platelet MAO-B amount. Moreover, such results 
obtained in two species (human and mice), with three cell types (platelets, PBMC, lung cells) 
and concerning two MAO isoenzymes, indicate that this smoking-induced MAO gene 
deregulation could have a more general impact than vascular modifications. 
Platelets from smokers were reported to show increased aggregability13 and to be more prone 
to spontaneous aggregation14. Platelet aggregation was, however, studied with platelet rich 
plasma or isolated platelets. Under similar conditions, we could not find any difference (not 
shown), the sensitivity of the turbidimetric method being too low. Platelet aggregation has 
also often been measured after acute smoking of 1-3 cigarettes, accounting for some 
discrepancies in the literature. Here, we measured platelet aggregation in whole blood, i.e. in 
the physiological platelet environment which might differ from one group to the other. Fitting 
with a trend for a higher fibrinogen plasma level (Supplementary Table 1) and thus a higher 
blood viscosity in S15, the collagen-induced aggregation velocity was significantly lower for S 
than for NS and FS. This result emphasizes the importance of studying platelet functions in 
whole blood.  
Platelet activation was reported for both acute and chronic smokers with more activation 
markers exposed on platelet surface16,17. The present results suggest that this smoking-induced 
platelet activation may not be sufficient to release the stored 5-HT from dense granules since 
it was found similar in platelets from S or NS. Only FS platelets had lower levels of 5-HT, a 
finding fitting with the deficiency of the vesicular monoamine transporter reported in platelets 
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of smokers18 leading to a platelet dense granule 5-HT storage defect. Accordingly, we found a 
higher 5-HIAA level in FS plasma. The untransformed 5-HT dispersed from platelet to 
plasma is largely diluted, and plasma 5-HT concentrations were not significantly different 
between the three groups (not shown).  
To account for the higher level of 5-HIAA in FS plasma, platelet MAO-B could be either 
more active or in higher quantity, inasmuch that we did not find any difference in other 
possible 5-HT metabolites (sulfo- and nitro(so)-conjugates, not shown). So far, MAO-B 
activity was repeatedly reported to be lower in current smokers than in non smokers2,7,8,19. 
Here, we report that the FS group accounts for the significantly higher platelet MAO-B 
activity found in “presently-non-smokers”. More noticeably, the platelet MAO amount was 
elevated in FS and also in S. One could thus expect that more MAO-B protein would result in 
high MAO-B activity in the two groups. Yet, this was only true for FS but not for S. By 
calculating the MAO-B catalytic activity, we found that the lowest was that of S platelets, 
reasserting the low MAO-B activity of current smokers2,7,8. This is consistent with the fact 
that MAOs are oxygen-dependent and carbon monoxide-inhibited enzymes2. This inhibition 
of MAO-B catalytic activity during smoking is also in agreement with PET-scan data 
obtained with brain19 and peripheral organs20 of smokers, non-smokers and ex-smokers using 
a radiotracer which binds irreversibly to MAO-B: on average MAO-B is inhibited by over 
40% in smokers vs. non-smokers with no significant difference between brains of non- and 
ex-smokers. Two reports assessing whether MAO inhibition could recover after an overnight 
abstinence21 or after 10-31 days of smoking abstinence22 led to the conclusions that (i) the 
enzyme is irreversibly inhibited by compounds in cigarette smoke, and (ii) after smoking 
cessation, MAO activity probably returns to normal through de novo synthesis of the enzyme. 
Our present report not only confirms but enlarges and promotes these two deductions with the 
elucidation of the mechanism regulating MAO-B inhibition and slow recovery. 
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We showed here that MAO activity was inhibited during smoking and restored after quitting, 
whereas MAO amount was increased during smoking and remained high many years after 
quitting. From a mechanistic point of view, the persistence of increased amounts of MAO-B 
was unexpected, even though some haematological and inflammation characteristics remain 
modified for several years after quitting smoking6,23,24. Modifications regarding the gene 
encoding MAO-B might bring a new explanation. Three recent studies identify an association 
between genetic variation on chromosome 15, in a region containing the gene encoding the 
nicotinic acetylcholine receptor, and risk of lung cancer25-27. A SNP is clearly linked to 
smoking quantity level26. Here we demonstrated how epigenetics may also participate to 
tobacco addiction and its long-lasting effects after quiting. A higher methylation of MAOA 
was found associated with nicotine- and alcohol-dependence29 in women whereas a down-
regulation of MAOA transcription was reported in several cancers including lung cancer28. 
Here we found that both S and FS exhibited a reduced methylation of the MAOB promoter, 
leading to a more active transcription of the gene and hence a higher MAO-B amount. 
Moreover, our ex vivo animal experiments showing that tobacco smoke induced an increase of 
nucleic acid demethylase activity give support to the fact that reduction in the MAOB 
promoter methylation is actually due to smoking. This is the first report showing that smoking 
has a long-lasting effect in modifying MAOB transcription. So far, the latter had only been 
shown during the differentiation of a human colon adenocarcinoma cell line9. DNA 
methylation is a covalent modification associated with long-term gene silencing and potential 
links to tumorigenesis10 and suicide30. Thus, the epigenetic process found in the present 
report, which regulate gene activity without altering the DNA code, might explain at least 
some of the reported long-lasting effects and health problems generated by smoking6,23,24. 
Now, the nucleic acid demethylase activity, which we found increased by tobacco smoke, 
generates aldehydes31,32 (Fig. 4). The latter are able to further cyclize bioamines, and from 5-
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HT to generate, among others, β-carbolines such as harman or norharman2,11,12. Smoking 
periods might, thus, keep the MAO inhibited, contributing to a sustained 5-HT 
neurotransmission, and therefore mimicking an antidepressant effect (Fig. 4). In addition, 
being inverse agonists of GABA-A receptors, β-carbolines are involved in mood regulation 
and more precisely in anxious states. Accordingly, several data indicate that tobacco smoke is 
an anti-depressive addict2,8,33. About half of the patients studied here were submitted to an 
anxiety-depression questionnaire (not shown). All of these were underscored, i.e. below the 
characteristic threshold scores for depression and anxiety, indicating that none of the 
evaluated patients was presenting with any patent anxio-depressive disease. As previously 
reported22,33, we observed that the S group was the most proned to depression. One can 
therefore speculate that smokers, instead of using a MAO inhibitor or another antidepressant, 
need to inhibit their MAO by smoking. In this context, epigenetic modifications have been 
reported for psychiatric disorders in animal models34. Our present finding is the first report of 
an epigenetic modification in human smokers. 
In conclusion, as it is increasingly evident that 5-HT is at the crossroads of cardiovascular and 
depressive diseases35, we suggest that MAO could be a determinant player at this cross-
section (Supplementary data including Supplementary Fig. 2) as it is already for alcoholic 
addiction36 and for predisposition to lung cancer26,28. A best understanding of the epigenome 
may open new fields of investigation in elucidating phyiopathology and developing new 
therapeutic approaches in tobacco addiction. 
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METHODS 
Subjects. The studied population was selected as 115 consecutive men aged from 35 to 56 
years free from cardiovascular disease including stroke, transient ischemia, coronary heart 
disease, congestive heart failure and intermittent claudication. Patients referred to the “Centre 
de Médecine Préventive Cardio-Vasculaire” between January 2003 and January 2007 for 
cardiovascular risk assessment were included in the study (i) if they had one or more mild 
cardiovascular risk factors among hypertension (defined as systolic blood pressure (BP) 
between 140 and 160 mm Hg and/or diastolic BP between 90 and 95 mm Hg), 
hypercholesterolemia (defined as total cholesterol measured by usual enzymatic methods after 
subjects had fasted for 14 hours between 5.2 and 7.2 mmol/L) and smoking; (ii) if they were 
free from diabetes (fasting blood glucose level < 7 mmol/L), from obesity (body mass index < 
30 kg/m²) and from antihypertensive, lipid-lowering, antidiabetic and platelet antiaggregant 
therapies. Usual biological variables were measured on an LX20 automate (Beckman-Coulter) 
using various kits (creatinine, CRP, triglycerides, total, HDL and LDL cholesterol, lipoprotein 
a, folates, homocysteine, glucose) and procedures according to the manufacturer’s 
instructions. Ten-year risk of coronary event was calculated by the Framingham equations on 
the basis of age, gender, systolic BP, total to HDL cholesterol ratio, and smoking37. Relative 
risk (RR) was calculated as the actual divided by the ideal (normotensive, 
normocholesterolemic, non smoker subject for each age category) 10-year coronary risk. A 
genetic approach had not been considered when patients were recruited. We thus undertook a 
new study on a small additional series of patients with consents for a genetic study but 
without authorization for human lung biopsies. All clinical investigations were conducted 
according to the Declaration of Helsinki principles and informed consents were obtained from 
 14
all subjects prior to inclusion in the study. The local Research Ethics Board approved the 
study protocols (CPP AP-HP 06-223).  
 
Smoking status and classification. Smoking status, duration of smoking, number of years 
since quitting and lifelong smoking dose (calculated by multiplying the mean number of 
cigarettes smoked daily by the number of years of smoking and expressed in pack-year) were 
carefully assessed by questioning the subjects. The latter were classified into three groups on 
the basis of their smoking status: (i) never smokers (NS); (ii) current smokers (S) – those who 
currently smoke daily or have smoked for the previous year, regardless of the amount 
smoked; and (iii) former smokers (FS) - those who have smoked, but have quitted one year 
ago or more. Occasional smokers who had not quitted for at least one year were not included 
in the study.  
 
Materials and reagents. The high-resolution B-mode Ultramark 5000 echograph was from 
Philips (Les Ulis, F). The aggregometer was from Coulter (Villepinte, F). HPLC-grade 
acetonitrile was obtained from VWR, Strasbourg, F); 5-HT binoxalate, ascorbic acid, and 
potassium dihydrogen phosphate were from Fluka (Coger, Paris, F), EDTA and sodium 
metabisulfite (Na2S2O5) were from British Drug House (Poole, UK). All other reagents were 
at least of analytical reagent grade from Sigma-Aldrich (St Quentin-Fallavier, F). Reagent-
grade water, obtained from a Millipore MilliQ-system (St-Quentin-Fallavier, F), was used 
throughout. 
 
Ultrasound Investigation. Ultrasonography was performed by experienced sonographer 
physicians using a 7.5 MHz probe for the extracranial carotid and femoral arteries and a 3-
MHz probe for the abdominal aorta, as previously described38. At each of the three sites, data 
were classified into two categories: absence of any atherosclerotic plaque and presence of one 
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or more arterial plaque(s), regardless of the precise location and number. The intima media 
thickness (IMT) was measured on the common carotid artery on both sides in the far wall of 
at least 1 cm of longitudinal length, and calculated by a program as previously described39. 
 
Platelet, PBMC and plasma preparation, platelet aggregation. Blood was drawn from 
antecubital veins of fasting subjects in 3.8 % sodium citrate-anticoagulated tubes (1:10 v/v). 
Whole blood aggregometry was measured using 500 µL aliquots of blood diluted 1:1 (v/v) in 
saline under constant stirring by the impedance technique, after addition of 3 μg/mL of 
collagen. Platelet rich plasma (PRP) was obtained by 10 min centrifugation at 100g (20°C) 
and platelet poor plasma (PPP) by 10 min centrifugation at 20°C and at 1500g. PRP and PPP 
samples were stored at - 80°C until further analysis (within 2 weeks). PBMC were obtained 
from each patient of the additional series using the standard Ficoll-Hypaque procedure. 
 
Serotonin and 5-HIAA measurements. Serotonin and its deaminated metabolite 5-HIAA 
were measured using HPLC, as described by Kema et al.40 in PRP and PPP samples, 
respectively.  
 
MAO activities and amounts. MAO (EC.1.4.3.4.) enzymatic activity was determined as 
previously reported8 on human PRP or PBMC samples by a radioenzymatic assay using [14C]-
β-phenylethylamine (2.07 GBq/mmol, Amersham GE Healthcare, Saclay, F, final 
concentration 20 µM, Michaelis constant 1.25 µM) as substrate. The MAO activity measured 
by this method is fully accounted for by MAO-B (the only isoform present in human platelets 
and PBMC)41.Platelet MAO-B amount was assessed for each patient by measuring the 
binding of [3H]Ro 19-6327 [N-(2-aminoethyl)-5-chloropicolinamide HCl, lazabemide] (0.96 
TBq/mmol, Amersham GE Healthcare), a reversible inhibitor of MAO-B, to human platelet 
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membranes, as described by Cesura et al.42 for [3H]Ro 16-6491. Platelets in PRP and PBMC 
(only on the additional series of patients) samples were lysed by an SH-dependent toxin as 
previously described43 in Tris buffer (50 mM Tris, 130 mM NaCl, 5 mM KCl, 0.5 mM 
EGTA, 1 mM MgCl2, pH 7.40; 10 mg protein/ml) before incubation for 1 h at 20°C in the 
presence of 50 nM of [3H]Ro 19-6327. Incubation was terminated by addition of cold Tris 
buffer and 2 min centrifugation at 12,000 g at 4°C. The pellets were rinsed and solubilized in 
200 µL of SDS (20%, wt/vol) for radioactivity counting. The amount of not specifically 
bound [3H]Ro 19-6327 was determined in the presence of 10 µM l-deprenyl. The non specific 
binding due to plasma was also deduced. The same protocol was applied to human PBMC, 
mouse platelets and mouse lungs. MAO-A activities and amounts in mouse lungs were 
determined exactly as for MAO-B except that [14C]-5-HT creatinine sulfate (1.96 GBq/mmol, 
Amersham GE Healthcare, Saclay, F,) and [3H]Ro 41-1049 (0.31 TBq/mmol, Amersham GE 
Healthcare) were used as substrate and radioligand respectively. Platelet MAO-B amount was 
also assessed by western blot. Briefly, samples were collected from S, NS, and FS patients in 
order to obtain a total of 10 µg protein (protein concentration was determined by the 
bicinchoninic acid method, Pierce, Chichester, UK). Proteins were resolved by 4-12% Bis-
Tris NuPAGE. Separated proteins were electrotransferred to polyvinylidene difluoride 
membrane (Novex, San Diego, CA) and incubated with specific antibody to MAO-B (C-17, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA) and MAO-B detected by the ECL system 
(Amersham GE Healthcare). 
 
Sodium bisulfite genomic sequencing of the MAO-B gene promoter. Genomic DNA was 
obtained from PBMC of each patient of the additional series using standard procedures. 
Bisulfite treatments were performed as described44 with minor modifications. Briefly, 
genomic DNA (1 µg) was denaturated in 0.2 M NaOH at 42°C for 20 min and then mixed 
with 10 mM hydroquinone and 3 M sodium bisulfite (pH 5.0). Reactants were incubated at 
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55°C for 18 h, and bisulfite-modified DNA was purified using the Wizard purification resin 
(Promega, Madison, WI, USA) and eluted into water. A fragment of the genomic DNA of the 
MAOB gene promoter (Genbank M89637 5’flanking sequence -55 to -752 bp, +1 assigned to 
the start of translation) was amplified using the following primers: 5’-
GCCTTCCTGACTTAATCAC-3’ (forward -752) and 5’-CCTCGATCCCAGTCCTGCC-3’ 
(reverse -55). PCR amplification was performed in 50 µL reaction mixture containing 5 µL of 
bisulfite-modified DNA, 0.5 µM primers, 100 µM dNTPs, 2 mM MgCl2, 50 mM KCl, 10 mM 
Tris-HCl (pH 8.30), and 2.5 units of Taq polymerase (Invitrogen, Carlsbad, CA, USA). The 
PCR conditions were: 97°C for 4 min (1 cycle) and 95°C for 1 min, 56°C for 1 min, 72°C for 
2 min (30 cycles). PCR products amplified from each blood sample were cloned into pCR II 
and sequenced. 
 
DNA methyltransferase and nucleic acid demethylase activities of mouse lung. Male A/J 
mice, aged 6 to 8 weeks, were purchased from Charles River (Orléans, F) and allowed to 
acclimate for 2 weeks before the start of the study. Mice were exposed to filtered air or 
mainstream cigarette smoke (10 mice in each group) using the exposure regimen developed 
by Witschi et al.45 at a concentration of 250 mg/m3 for 5.5 hours/day, 5 days/week for 5 
months, and sacrificed. Nuclear extracts were prepared from lungs according to the protocol 
of Dignam et al.46. Their DNA methyltransferase activity was determined as described 
previously47. The nucleic acid demethylase activity of the mouse lung nuclear extracts was 
assayed as their ability to demethylate 3-methylcytosine in [14C]-methylated poly(dC). The 
substrate was generated by treatment of poly(dC) with [14C]-methyl iodide (1.91 GBq/mmol, 
Amersham GE Healthcare). Demethylation was assayed by measuring the release of [14C]-
formaldehyde as described previously32. Briefly, reaction mixtures contained 50 mM Tris-
HCl pH 7.50, 1 mM 2-oxoglutarate, 2 mM ascorbate, 75 µM (NH4)2Fe(SO4)2, 50 µg/mL BSA 
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and the [14C]-methylated poly(dC) (approximately 10,000 dpm) in a total volume of 100 µL, 
and were incubated at 37°C for 30 minutes. The reactions were stopped by the addition of 
EDTA to a final concentration of 10 mM and the ethanol-soluble radioactive material was 
monitored by scintillation counting. All animal experimentation was performed in accordance 
with institutional guidelines. Protocols were approved by the French Animal Care Committee 
in accordance with European regulations.  
Statistical analysis. It was carried out with the use of JMP (SAS) and Excel (Microsoft) 
softwares. For all tests, statistical significance was set at P < 0.02 (α, two-sided type 1 error 
of < 2 %). 
Overall study sample. Continuous parameters are expressed as means ± SD. Normality of the 
distribution was analyzed by the Shapiro-Wilk W test. Normally-distributed variables were 
compared between smoking status groups by ANOVA, pairwise comparisons being 
performed by using the Student’s t-test. Non normally-distributed variables were compared 
between smoking status groups by non parametric (Wilcoxon and Kruskal-Wallis) tests. 
Qualitative parameters are expressed as percent of subjects and compared between smoking 
status groups by the chi-square test. Linear regressions were used to analyze the relationships 
between continuous parameters, after logarithmic transformation in the case of non normal 
distribution.  
Patients selected for the genetic study and mice studies. Enzyme activities and amounts were 
compared between groups by Fisher’s exact test. 
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Figure Legends 
 
Figure 1: Platelet 5-HT catabolism according to smoking status. 
PRP 5-HT (1A) and PPP 5-HIAA (1B) were measured by HPLC in samples of 34 NS, 44 S 
and 37 FS. Results are means of nmoles 5-HT/109 platelets and of nM 5-HIAA. Bars 
represent standard deviations. Significance: *P<0.001. All 5-HT values were within the 
normal range (0.5-5.0 nmoles/109 platelets), ensuring that none of the patients studied was 
presenting with a storage pool disease. 
Platelet MAO-B activities (1C) were determined on PRP samples of 34 NS, 44 S and 37 FS 
by radioenzymology. Results are given in nmoles of substrate per mg protein and per hour. 
Platelet MAO-B amounts (1D) were assessed both by Western blot and by measuring the 
binding of a reversible inhibitor of MAO-B to platelet membranes of 34 NS, 44 S and 37 FS 
and expressed as pmoles of MAO-B per mg platelet protein. Results are mean values and bars 
represent standard deviations. Significance: *P<0.001; ‡P<0.00001.  
 
Figure 2: Analysis of the MAO-B gene promoter methylation status.  
A Left: methylation frequencies at each CpG site within the human MAO-B gene core 
promoter. Values (%) are means for each group (4 NS, 5 S, and 4 FS). A Right: mean 
methylation frequency of the 22 CpG sites of the MAO-B gene promoter according to the 
smoking status (4 NS, 5 S, 4 FS) (*P<0.0001).  
B: correlation between the mean methylation frequencies of the MAO-B gene promoter 22 
CpG sites and the platelet MAO amounts (n = 13, r = 0.70, P<0.001).  
Insert: platelet MAO activities (nmoles.mg protein-1.h-1) and amounts (pmoles.mg protein-1) 
according to the smoking status of the patients selected for the genetic study (4 NS, 5 S, 4 
FS). Significance: *P<0.02 
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Figure 3: Effect of cigarette smoke on DNA methyltransferase and nucleic acid 
demethylase activities.  
Mice (10 for each group) were exposed (Sm) or not (NSm) to cigarette smoke and enzyme 
activities (A: DNA methyltransferase, B: nucleic acid demethylase, and C: MAO-A and 
MAO-B) determined on lung extracts as described in methods. Results are expressed as 
means ± SD. Insert: platelet MAO activities (nmoles.mg protein-1.h-1) and amounts 
(pmoles.mg protein-1) according to the smoking status of mice. Significance: *P<0.001 
 
Figure 4: Effect of cigarette smoke on serotonin (5-HT) catabolism. 
Cigarette smoke stimulates the nucleic acid demethylase activity (1.) which generates 
aldehydes (HCHO) and demethylates the MAO promoter gene (2.). The demethylated MAO 
promoter gene leads to increased MAO amount (4.). Aldehydes, together with 5-HT and upon 
the action of methylene tetrahydrofolate reductase (3. MTHFR), lead to the formation of β-
carbolines, such as harman and norharman. The latter are known inhibitors of MAO activity 
(5.) and, being present in cigarette smoke*, keep the sequence 1-5 switched on in smokers. 
The β-carbolines also act on GABA-A receptors, thus contributing to mood regulation as do 
MAO and 5-HT. Noteworthy, the MTHFR activity does not appear to be the limiting step in 
this process since folates were not significantly different between smokers and non smokers 
(cf. supplementary Table 1). 
*The in vivo levels of plasma harman (6.8 nM) and norharman (20.02 nM) reported in 
smokers 48 might, however, be high enough to affect nucleic acid demethylase activity, as it is 
the case for platelet MAO-B inhibition48. 
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SMOKING STATUS 
 
Parameter Non smokers (NS) Smokers (S) Former Smokers (FS) P Value 
 n = 34 (29.6%) n = 44 (38.2%) n = 37 (32.2%)  
     
Smoking parameters    (S vs FS) 
   cigarettes per day 0 19 ± 3 0 - 
   yrs of smoking 0 23 ± 1 18 ± 2 0.02 
   yrs since quitting 0 0 13 ± 8 - 
   packs.yrs 0 23 ± 17 18 ± 11 0.15 
      
Inflammation and blood profile    (overall) 
   C reactive protein, mg/L 1.3 ± 1.2 2 ± 2  2 ± 3  0.10 
   fibrinogen, g/L 2.8 ± 0,5 3.1 ± 0.5 3 ± 0.4 0.06 
   hematocrit, % 42 ± 2 44 ± 3 43 ± 2 0.06 
   hemoglobin, g/100 mL 14.4 ± 0.7 14.8 ± 0.8 15 ± 1 0.10 
   leukocytes, G/L 5 ± 1 7 ± 2 6 ± 1 0.0001  
   platelets, G/L 224 ± 41 224 ± 55 242 ± 46 0.23 
     
Atheromatous profile    (overall) 
   presence of plaque at any site, n (%) 14 (41) 31 (70.5) 22 (59.5) 0.05 
   presence of carotid plaque, n (%) 9 (26.5) 19 (43) 10 (27) 0.21 
   presence of femoral plaque, n (%) 9 (26.5) 29 (66) 16 (43) 0.002 
   presence of aortic plaque, n (%) 7 (21) 16 (36) 8 (22) 0.21 
     
Intima media thickness, mm 0.56 ± 0.07 0.60 ± 0.10 0.60 ± 0.10 0.55 
     
 
Table 1. Smoking, inflammation, blood parameters and atheromatous profile of 115 patients according to their smoking status. Data are 
means ± SD, or number and percent of subjects n (%). 
